Similar substrate specificity of cynomolgus monkey cytochrome P450 2C19 to reported human P450 2C counterpart enzymes by evaluation of 89 drug clearances

被引:7
|
作者
Hosaka, Shinya [1 ,2 ]
Murayama, Norie [1 ]
Satsukawa, Masahiro [2 ]
Uehara, Shotaro [1 ]
Shimizu, Makiko [1 ]
Iwasaki, Kazuhide [3 ]
Iwano, Shunsuke [1 ,4 ]
Uno, Yasuhiro [3 ]
Yamazaki, Hiroshi [1 ]
机构
[1] Showa Pharmaceut Univ, Machida, Tokyo 1948543, Japan
[2] Kaken Pharmaceut Co LTD, Shizuoka 4268646, Japan
[3] Shin Nippon Biomed Labs Ltd, Kainan, Wakayama 6420017, Japan
[4] Novartis Pharma KK, Tokyo 1068618, Japan
关键词
cynomolgus monkey; CYP2C19; substrates; loratadine; LIVER-MICROSOMES; METABOLISM; CYP2C19; IDENTIFICATION; INHIBITION; POLYMORPHISMS; TOLBUTAMIDE; CLOPIDOGREL; LORATADINE; WARFARIN;
D O I
10.1002/bdd.1991
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cynomolgus monkeys are used widely in preclinical studies as non-human primate species. The amino acid sequence of cynomolgus monkey cytochrome P450 (P450 or CYP) 2C19 is reportedly highly correlated to that of human CYP2C19 (92%) and CYP2C9 (93%). In the present study, 89 commercially available compounds were screened to find potential substrates for cynomolgus monkey CYP2C19. Of 89 drugs, 34 were metabolically depleted by cynomolgus monkey CYP2C19 with relatively high rates. Among them, 30 compounds have been reported as substrates or inhibitors of, either or both, human CYP2C19 and CYP2C9. Several compounds, including loratadine, showed high selectivity to cynomolgus monkey CYP2C19, and all of these have been reported as human CYP2C19 and/or CYP2C9 substrates. In addition, cynomolgus monkey CYP2C19 formed the same loratadine metabolite as human CYP2C19, descarboethoxyloratadine. These results suggest that cynomolgus monkey CYP2C19 is generally similar to human CYP2C19 and CYP2C9 in its substrate recognition functionality. Copyright (C) 2015 John Wiley & Sons, Ltd.
引用
收藏
页码:636 / 643
页数:8
相关论文
共 50 条
  • [1] Human Cytochromes P450: Focus on Cytochrome P450 2C19
    Zvyaga, Tatyana
    Chang, Shu-Ying
    Chen, Cliff
    Yang, Zheng
    Vuppugalla, Ragini
    Hurley, Jeremy
    Thorndike, Denise
    Wagner, Andrew
    Chimalakonda, Anjaneya
    Rodrigues, A. David
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (09) : 1698 - 1711
  • [2] Cytochrome P450 2C19 genetic polymorphisms in Ugandans
    Miura, Jun
    Obua, Celestino
    Abbo, Catherine
    Kaneko, Sunao
    Tateishi, Tomonori
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (03) : 319 - 320
  • [3] Cytochrome P450 2C19 genetic polymorphisms in Ugandans
    Jun Miura
    Celestino Obua
    Catherine Abbo
    Sunao Kaneko
    Tomonori Tateishi
    European Journal of Clinical Pharmacology, 2009, 65 : 319 - 320
  • [4] Human Hepatic Cytochrome P450 2C Metalloenzymes and Drug Metabolism
    Jiang Hualin
    Tan Xiangshi
    PROGRESS IN CHEMISTRY, 2009, 21 (05) : 911 - 918
  • [5] EXPRESSION AND CHARACTERIZATION OF HUMAN CYTOCHROME-P450 2C ENZYMES IN ESCHERICHIA-COLI, IDENTIFICATION OF P450 2C19 AS A PROGESTERONE 21-HYDROXYLASE
    RICHARDSON, TH
    JUNG, F
    GRIFFIN, KJ
    WESTER, M
    RAUCY, JL
    JOHNSON, EF
    FASEB JOURNAL, 1995, 9 (06): : A1489 - A1489
  • [6] Identification of putative substrates for cynomolgus monkey cytochrome P450 2C8 by substrate depletion assays with 22 human P450 substrates and inhibitors
    Hosaka, Shinya
    Murayama, Norie
    Satsukawa, Masahiro
    Uehara, Shotaro
    Shimizu, Makiko
    Iwasaki, Kazuhide
    Iwano, Shunsuke
    Uno, Yasuhiro
    Yamazaki, Hiroshi
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2016, 37 (05) : 310 - 313
  • [7] The Structure of Human Cytochrome P450 2C19: Active site differences between P450s 2C19 and 2C9
    Reynald, Rosamund L.
    Sansen, Stefaan
    Stout, C. David
    Johnson, Eric F.
    FASEB JOURNAL, 2008, 22
  • [8] In Vitro Assessment of Cytochrome P450 2C19 Potential of Naoxintong
    Chen, Hui
    Zhang, Ya
    Wu, Xiaoying
    Li, Candong
    Wang, Huan
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2012, 2012
  • [9] Is 17 α-ethinyl estradiol an inhibitor of cytochrome P450 2C19?
    Rodrigues, AD
    Lu, P
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (03) : 364 - 365
  • [10] Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19
    R Timm
    R Kaiser
    J Lötsch
    U Heider
    O Sezer
    K Weisz
    M Montemurro
    I Roots
    I Cascorbi
    The Pharmacogenomics Journal, 2005, 5 : 365 - 373